A US Senate committee has proposed continuing a federal spending rider that protects state medical cannabis programmes from Justice Department interference, while declining to copy a House measure that would block the Trump administration’s plans to reschedule cannabis. The details were first reported by Marijuana Moment.
The Senate Appropriations Committee posted its Fiscal Year 2027 Commerce, Justice, Science and Related Agencies spending bill on Thursday. It includes an updated version of the provision that has been part of federal law since 2014. It bars the Department of Justice from using its funds to stop listed states, the District of Columbia and US territories from implementing their own medical cannabis laws.
What the Senate version leaves out
The Senate text does not include two additions that the House Appropriations Committee proposed in May. One would have stated that the Justice Department can still enforce a section of federal law that increases penalties for distributing cannabis within 1,000 feet of schools, colleges, playgrounds or public housing.
The other would have prevented federal funds from being used "to reschedule marijuana" or to remove it from the schedules of the Controlled Substances Act. According to Marijuana Moment, the Trump administration has already moved state-licensed medical cannabis from Schedule I to Schedule III, and a Drug Enforcement Administration hearing is considering a wider move of cannabis to Schedule III. No equivalent language appears in the Senate bill.
The Senate bill also keeps a separate rider protecting state industrial hemp research programmes from interference by the Justice Department and the DEA.
Reports requested from agencies
The committee report attached to the spending bill directs the Justice Department to report to Congress within 90 days of enactment on illegal cannabis growing operations linked to foreign nationals. The report would be coordinated among the FBI, the DEA and the Executive Office for United States Attorneys. It would assess the extent of such operations, any links to Chinese transnational criminal organisations or the Chinese government, and the federal resources that could support state, local and tribal law enforcement.
The report also asks the DEA for a briefing within 60 days on the health and safety impacts of kratom products. It notes that in 2025 the Department of Health and Human Services referred a byproduct of the kratom plant to the DEA for possible scheduling.
A report attached to a separate Department of Homeland Security funding bill directs Customs and Border Protection to brief Congress within 120 days on seizures of cannabis products from distributors operating in line with state or tribal law. Marijuana Moment said the issue has been the subject of litigation and criticism from New Mexico Governor Michelle Lujan Grisham.
What happens next
Earlier this week the committee released other funding bills and reports. According to Marijuana Moment, these ask federal agencies to consider medical cannabis as an alternative to opioids and the therapeutic potential of psychedelics, encourage work on hemp cultivars and germplasm, and raise concerns about cannabinoid-infused foods.
The panel has not yet scheduled votes on any of the measures. The House and Senate versions would need to be reconciled before any spending bill becomes law.
The story matters to UK readers because US federal decisions on cannabis scheduling and enforcement are often watched internationally. In the UK, cannabis remains a Class B drug under the Misuse of Drugs Act 1971, though specialist doctors have been able to prescribe cannabis-based medicines since 1 November 2018.

Join the conversation
Be the first to have your say.
Should governments protect state medical cannabis programmes from federal interference, and what would that mean for patients where you live?